Notes And Other Explanatory Information [Abstract]

Egetis Therapeutics - Filing #676549

Concept 2023-01-01 to
2023-12-31
Notes and other explanatory information [abstract]
Disclosure of accounting judgements and estimates [text block]
NOT
Disclosure of allowance for credit losses [text block]
Kreditrisk  
Disclosure of auditors' remuneration [text block]
NOT
Disclosure of authorisation of financial statements [text block]
Årsredovisning och koncernredovisning för räkenskapsåret 1  
Disclosure of business combinations [text block]
förvärvade identifierbara tillgångar samt övertagna skulder  
Disclosure of cash flow statement [text block]
NOT
Disclosure of changes in accounting policies, accounting estimates and errors [text block]
Nya och ändrade standarder som tillämpas 2023  
Disclosure of collateral [text block]
NOT
Disclosure of debt instruments [text block]
Finansiella skulder värderade till upplupet anskaffningsvärde  
Disclosure of deferred income [text block]
NOT
Disclosure of deferred taxes [text block]
Koncernens outnyttjade skattemässiga underskott beräknas till 1 370 (1 027) MSEK och moderbolagets  
Disclosure of derivative financial instruments [text block]
Verkligt värde  
Disclosure of dividends [text block]
NOT
Disclosure of earnings per share [text block]
NOT
Disclosure of effect of changes in foreign exchange rates [text block]
NOT
Disclosure of employee benefits [text block]
Ersättningar  
Disclosure of entity's operating segments [text block]
NOT
Disclosure of events after reporting period [text block]
NOT
Disclosure of expenses [text block]
Nyttjanderättstillgången värderas initialt till nuvärdet av de  
Disclosure of finance cost [text block]
Koncernen  
Disclosure of financial risk management [text block]
NOT
Disclosure of general information about financial statements [text block]
NOT
Disclosure of impairment of assets [text block]
Prövning av nedskrivningsbehov av Forsknings- och utvecklingskostnader  
Disclosure of income tax [text block]
NOT
Disclosure of information about employees [text block]
NOT
Disclosure of information about key management personnel [text block]
NOT
Disclosure of interest income [text block]
NOT
Disclosure of interests in other entities [text block]
NOT
Disclosure of lease prepayments [text block]
NOT
Disclosure of leases [text block]
I tabellen nedan analyseras koncernens finansiella skulder uppdelade e
Disclosure of liquidity risk [text block]
Likviditetsrisk  
Disclosure of market risk [text block]
Valutarisk  
Disclosure of material accounting policy information [text block]
NOT
Disclosure of other current liabilities [text block]
Finansiella tillgångar värderade till upplupet anskaffningsvärde  
Disclosure of other operating income (expense) [text block]
NOT
Disclosure of other provisions, contingent liabilities and contingent assets [text block]
NOT
Disclosure of property, plant and equipment [text block]
NOT
Disclosure of research and development expense [text block]
NOT
Disclosure of revenue from contracts with customers [text block]
Försäljnignsintäkter fördelar sig  
Disclosure of share capital, reserves and other equity interest [text block]
NOT
Disclosure of share-based payment arrangements [text block]
NOT
Disclosure of subordinated liabilities [text block]
NOT
Disclosure of trade and other receivables [text block]
Koncernen

Talk to a Data Expert

Have a question? We'll get back to you promptly.